# Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

> **NCT04060147** · PHASE1 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 11 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis
- Compensated Cirrhosis

## Interventions

- **DRUG:** Cilofexor

## Key facts

- **NCT ID:** NCT04060147
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-17
- **Primary completion:** 2021-09-02
- **Final completion:** 2021-09-02
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** The study enrollment was terminated early by the sponsor due to recruitment challenges.
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04060147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04060147, "Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04060147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*